Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emergence of piperacillin/tazobactam-resistant Escherichia coli.

× No keyword cloud information.

5 in total

1. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.

Authors: D Vanjak; C Muller-Serieys; B Picard; E Bergogne-Berezin; N Lambert-Zechovsky
Journal: Eur J Clin Microbiol Infect Dis Date: 1995-11 Impact factor: 3.267

2. Escherichia coli: epidemiology and analysis of risk factors for infections caused by resistant strains.

Authors: D Lepelletier; N Caroff; A Reynaud; H Richet
Journal: Clin Infect Dis Date: 1999-09 Impact factor: 9.079

3. Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients.

Authors: K S Kaye; A D Harris; H Gold; Y Carmeli
Journal: Antimicrob Agents Chemother Date: 2000-04 Impact factor: 5.191

4. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.

Authors: B Brismar; A S Malmborg; G Tunevall; B Wretlind; L Bergman; L O Mentzing; P O Nyström; E Kihlström; B Bäckstrand; T Skau
Journal: Antimicrob Agents Chemother Date: 1992-12 Impact factor: 5.191

5. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group.

Authors: H C Polk; M P Fink; M Laverdiere; S E Wilson; G E Garber; P S Barie; J C Hebert; W G Cheadle
Journal: Am Surg Date: 1993-09 Impact factor: 0.688

5 in total

3 in total

1. Management of Pneumonia and Blood Stream Infections with New Antibiotic Adjuvant Entity (Ceftriaxone + Sulbactam + Disodium Edetate)- A Novel Way to Spare Carbapenems.

Authors: Mohammad Shameem; Mohammad Amin Mir
Journal: J Clin Diagn Res Date: 2016-12-01

2. Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical study.

Authors: Ismaël Mohammedi; Dominique Ploin; Serge Duperret; François Chapuis; Paul Petit
Journal: Intensive Care Med Date: 2003-05-27 Impact factor: 17.440

3. Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study.

Authors: Agnès Meybeck; Jean-Damien Ricard; Guilène Barnaud; Mathieu Eveillard; Guillaume Chevrel; Roman Mounier; Didier Dreyfuss
Journal: BMC Infect Dis Date: 2008-05-17 Impact factor: 3.090

3 in total